Halo is a clinical-stage biotechnology company creating first-in-class, disease-modifying therapies for the treatment of inflammatory and fibrotic diseases. Our first indication is pulmonary hypertension and interstitial lung disease.
We are building a differentiated pipeline based on novel insights into how extracellular matrix (ECM) dysregulation drives disease
Our primary target is Hyaluronan (HA), a key component of the ECM
Alterations to HA are associated with a variety of conditions characterized by inflammation and fibrosis, including pulmonary hypertension, pulmonary fibrosis, and liver fibrosis
Our lead pipeline candidate, H1614, is a reformulation of 4-methylumbelliferone, with the potential to be a first- and best-in-class hyaluronan (HA) remodeling agent for the treatment of patients with Group 3 pulmonary hypertension.
Preclinical and clinical data suggest that targeting the HA pathway can address the inflammation, fibrosis, and vascular remodeling associated with disease progression.